Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
0.6491
+0.0256 (4.11%)
Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer
The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQADAP), a company working...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQADAP), a company redefining...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQADAP), a company working to...
ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can...
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.
Adaptimmune Therapeutics plc (NASDAQADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
